Global News

[ad_1] Next week is one of the biggest of the year for health-care investors, and it has historically been a good time to own ETFs that track the industry. The 2023 JPMorgan Health Care Conference is set to kick off next Monday in San Francisco. The event features keynote speeches from the CEOs of Sage Therapeutics and Eli Lilly , as well as presentations from dozens of other health-care and biotech companies. The conference typically sees many companies preannounce quarterly results, revise outlooks and update investors about clinical trials. While those updates can break both ways for individual companies, they have recently been good news for the sector as a whole. Over the past five years, many of the biggest ETFs in health care and biotech have seen an average positive return in the first half of January, when the conference is typically held. The three funds below — the SPDR S & P Biotech ETF (XBI) , the Health Care Select Sector SPDR Fund (XLV) and the iShares U.S. Medi

[ad_1] Varda's first manufacturing satellite and reentry vehicle attached to a Rocket Lab Photon bus. Rocket Lab Space startup Varda received long-awaited approval from the Federal Aviation Administration to bring its first spacecraft back to earth after a stint manufacturing drugs in space. Varda's small W-Series 1 capsule, or W-1, has been stuck in orbit since it launched eight months ago. The company has awaited regulatory authorization to make a landing attempt in Utah, at the Air Force's Utah Test and Training Range. The FAA confirmed on Wednesday it had issued the license to Varda. The FAA's approval means Varda will try to land the W-1 mission on Feb. 21. "We are incredibly proud to have this opportunity with our government partners, and appreciate their dedication to safe innovation in the United States," Varda said in a statement. The W-1 mission is a demonstration of the company's automated in-space manufacturing process. Last year, Varda